Transgender hormone therapy (female-to-male) to individuals taking bioidentical hormones in the form of testosterone (including esters) and do not apply to those taking synthetic AAS (e.g., nandrolone) or dihydrotestosterone. Transgender hormone therapy (female-to-male) Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine (or androgynous) to masculine. It is one of two types of transgender hormone therapy (the other being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people
Adrenocortical hormone and increased blood potassium levels caused by a deficiency of aldosterone. These electrolyte imbalances induce nerve and muscle issues. Other symptoms include fatigue, salt cravings, weight loss, and increased skin pigmentation. Increased skin pigmentation is caused by a deficiency of the adrenocortical hormone hydrocortisone. Its normal behavior would be as negative feedback at the pituitary gland, stimulating the pituitary gland to decrease secretion of corticotropin. Because hydrocortisone is not able to be produced in Addison’s disease, the pituitary gland continues to secrete corticotropin which binds to the receptor for melanocyte-stimulating hormone. It then causes melanocytes to produce more pigment, thus